Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.44 |
| ▸ | HTR5A | P47898 | 9/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13366003 | 0.81 | HTR5A (0.48) | HTR5AALOX12MEN1KMT2A | |
| SCHEMBL31474673 | 0.81 | HTR5A (0.48) | HTR5AALOX12MEN1KMT2A | |
| SCHEMBL11897102 | 0.77 | EGFR (0.50) | EGFRALDH1A1SRCHTR5ACHRM1 | |
| SCHEMBL30088920 | 0.74 | BRPF1 (0.53) | ALDH1A1HTR5A | |
| SCHEMBL1879473 | 0.74 | HTR5A (0.43) | EGFRALDH1A1HTR5A | |
| SCHEMBL260994 | 0.74 | BRPF1 (0.53) | ALDH1A1HTR5A | |
| SCHEMBL19054962 | 0.74 | BRPF1 (0.53) | ALDH1A1HTR5A | |
| SCHEMBL117958 | 0.72 | CHRM1 (0.46) | CHRM1 | |
| SCHEMBL9833920 | 0.72 | PGR (0.42) | MEN1KMT2A | |
| SCHEMBL20385185 | 0.72 | HTR5A (0.48) | HTR5AALOX12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050282810-A1 | Oxindole derivatives | HARRIS PHILIP A | 2005-12-22 | — | — | US | disclosed |
| US-6964977-B2 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-15 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030225090-A1 | E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer | SMITHKLINE BEECHAM CORPORATION | 2003-12-04 | — | — | US | disclosed |
| EP-1317446-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-11 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2002020513-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| US-4289910-A | PROSTAGLANDIN ANALOGS | AMERICAN CYANAMID COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4252723-A | Air oxidation of oxindoles to isatins | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1981-02-24 | — | — | US | disclosed |
| US-4188325-A | Isatin process and products | REGENTS OF UNIVERSITY OF MINNESOTA (US) | 1980-02-12 | — | — | US | disclosed |
| US-4186132-A | Isatin products | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282810-A1 | Oxindole derivatives | OPRK1, ERBB2, OGFR | EGFR 133/4885ALDH1A1 3635/4885SRC 66/4885 |
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | EGFR 152/4885ALDH1A1 3649/4885SRC 46/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | EGFR 125/4885ALDH1A1 4171/4885SRC 10/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | EGFR 156/4885ALDH1A1 3290/4885SRC 1/4885 |
| US-20030225090-A1 | E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer | ERBB2, DSTYK, OPRK1 | EGFR 81/4885ALDH1A1 3801/4885SRC 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.